LDN for Crohn's
Crohn’s most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus. Ulcerative colitis is limited to the colon, also called the large intestine.When reading about inflammatory bowel diseases, it is important to know that Crohn’s disease is not the same thing as ulcerative colitis, another type of IBD. The symptoms of these two illnesses are quite similar, but the areas affected in the gastrointestinal tract (GI tract) are different. Crohn’s disease can also affect the entire thickness of the bowel wall, while ulcerative colitis only involves the innermost lining of the colon. Finally, in Crohn’s disease, the inflammation of the intestine can “skip”-- leaving normal areas in between patches of diseased intestine. In ulcerative colitis this does not occur.
- CureTogether Blog » Blog Archive » Crohn’s Study Results: 29 Treatments Rated by Patients
- Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial
- A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
- Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease
- Low dose naltrexone for induction of remission in Crohn's disease.
- Met-enkephalins in patients with inflammatory bowel disease
- Naltrexone as Therapy for Inflammatory Bowel Disease: Ulcerative Colitis and Crohn’s Disease
- Opioid G protein-coupled receptors: signals at the crossroads of inflammation
- Department of Health and Human Services
- SAFETY AND TOLERABILITY OF LOW DOSE NALTREXONE THERAPY IN CHILDREN WITH MODERATE TO SEVERE CROHN’S DISEASE: A PILOT STUDY
- Saftey and Tolerability of Low Doese Naltrexone Therapy in Children with Moderate to Server Crohn's Disease: A Pilot Study
- The role of IL-13 and NK T cells in experimental and human ulcerative colitis
- Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.